Targeted drugs for these markers, such as Herceptin (for HER2-positive breast cancer) and aromatase inhibitors (for ER-positive breast cancer), have proven effective in clinical settings [20,21,22]. The gene discussed is ERBB2; the disease is breast carcinoma.